PFE

PFE

USD

Pfizer Inc. Common Stock

$22.920+0.150 (0.659%)

リアルタイム価格

Healthcare
Drug Manufacturers - General
米国

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$22.770

高値

$23.100

安値

$22.475

出来高

3.95M

企業ファンダメンタルズ

時価総額

130.0B

業種

Drug Manufacturers - General

United States

取引統計

平均出来高

50.85M

取引所

NYQ

通貨

USD

52週レンジ

安値 $20.92現在値 $22.920高値 $31.54

関連ニュース

BusinessWire

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC)

もっと見る
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Reuters

Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds

A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

もっと見る
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
BusinessWire

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Guardant Health, Inc. (NASDAQ:GH), a

もっと見る
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
Reuters

Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales

Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.

もっと見る
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
CNBC

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.

もっと見る
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
BusinessWire

Pfizer Declares Second-Quarter 2025 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock,

BusinessWire

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer's industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。